Smarter Cancer Care
Genomic Health brings the promise of precision medicine
to life with Oncotype IQ, a full suite of genomic tests.

Landmark TAILORx Results

The long-awaited results of the Trial Assigning IndividuaLized Options for Treatment (TAILORx) definitively identified the vast majority of women with early stage breast cancer who will receive no benefit from chemotherapy, and the minority for whom chemotherapy can be life-saving.

What Is the Test
The Oncotype DX test reveals the underlying tumour biology to help guide treatment decisions.
Prognostic vs. predictive

Only a truly predictive test can identify the right treatment for the right patient

TAILORx

TAILORx results eliminate uncertainty around intermediate scores and show that most patients do not benefit from chemotherapy

Standard of Care

Only the Oncotype DX Breast Recurrence Score test is incorporated in the four major international guidelines and recommended by two major EU health technology assessment (HTA) bodies.

Contact Us

Get in Touch
Making cancer care smarter.™
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.